|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019929,
umls-concept:C0034802,
umls-concept:C0086418,
umls-concept:C0205225,
umls-concept:C0278488,
umls-concept:C0449438,
umls-concept:C0728747,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2011-5-3
|
|
pubmed:abstractText |
Recent studies have shown that the human epidermal growth factor receptor 2 status of a metastatic site may differ from that of the primary site. This difference may influence patient prognosis and response to therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/ERBB2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1465-3621
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
41
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
593-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21406492-Adult,
pubmed-meshheading:21406492-Aged,
pubmed-meshheading:21406492-Antibodies, Monoclonal,
pubmed-meshheading:21406492-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21406492-Antineoplastic Agents,
pubmed-meshheading:21406492-Bone Neoplasms,
pubmed-meshheading:21406492-Breast Neoplasms,
pubmed-meshheading:21406492-Disease-Free Survival,
pubmed-meshheading:21406492-Female,
pubmed-meshheading:21406492-Humans,
pubmed-meshheading:21406492-Immunohistochemistry,
pubmed-meshheading:21406492-In Situ Hybridization, Fluorescence,
pubmed-meshheading:21406492-Liver Neoplasms,
pubmed-meshheading:21406492-Lung Neoplasms,
pubmed-meshheading:21406492-Lymph Nodes,
pubmed-meshheading:21406492-Lymphatic Metastasis,
pubmed-meshheading:21406492-Middle Aged,
pubmed-meshheading:21406492-Neoplasm Staging,
pubmed-meshheading:21406492-Receptor, erbB-2,
pubmed-meshheading:21406492-Receptors, Estrogen,
pubmed-meshheading:21406492-Receptors, Progesterone,
pubmed-meshheading:21406492-Retrospective Studies,
pubmed-meshheading:21406492-Treatment Outcome,
pubmed-meshheading:21406492-Tumor Markers, Biological
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.
|
|
pubmed:affiliation |
Department of Internal Medicine, Seoul National University Hospital, 28 Yongon-Dong, Chongno-Gu, Seoul 110-744, South Korea.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
